Effect of resolvins on sensitisation of TRPV1 and visceral hypersensitivity in IBS.

Eluisa PernaJavier Aguilera-LizarragaMorgane V FlorensPiyush JainStavroula A TheofanousNikita HanningJoris G De ManMaya BergBenedicte De WinterYeranddy A AlpizarKarel TalaveraPieter Vanden BergheMira WoutersGuy Boeckxstaens

Published in: Gut (2020)

Our data suggest that RvD2 and GPR18 agonists may represent interesting novel compounds to be further evaluated as treatment for IBS.

Keyphrases

irritable bowel syndrome
insulin resistance
neuropathic pain
type diabetes
drug induced
combination therapy
spinal cord
deep learning
artificial intelligence